C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Company Overview - C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop new medicines that can transform patients' lives [2][4] - The company is leveraging its TORPEDO® platform to design and optimize small-molecule medicines aimed at difficult-to-treat diseases, particularly in oncology [4] Clinical Trial Information - C4T announced preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors [2][3] - The presentation of these preliminary results will take place at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, on September 14, 2024 [2][3] - CFT1946 is designed to be potent and selective against BRAF V600X mutant targets and has shown activity in preclinical studies in models with BRAF V600E driven disease and those resistant to BRAF inhibitors [3] Drug Development Focus - CFT1946 is currently being studied in a Phase 1 dose escalation trial for BRAF V600X mutant solid tumors, including colorectal cancer, melanoma, and non-small cell lung cancer [3] - The company's degrader medicines aim to utilize the body's natural protein recycling system to degrade disease-causing proteins, potentially overcoming drug resistance and improving patient outcomes [4]